Delivery Order SPE2DB25D2203-SPE2DB26FPRAS
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $4,165.68 to AmerisourceBergen Drug Corp for the supply of Repatha 140 mg/ml SureClick auto-injector pens. This competitive contract, executed on August 13, 2025, with an ultimate completion date of August 14, 2025, represents a firm fixed-price delivery order with no set-aside designation. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency awarded a $9,272.65 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injector pens, with an ultimate completion date of September 4, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and running through December 2026. The pharmaceutical product will be delivered to...
- The Defense Logistics Agency awarded a delivery order valued at $15,153.17 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injector pens. The contract, issued on June 2, 2025, with completion targeted for June 3, 2025, utilizes firm fixed-price pricing with no set-aside designation, indicating competitive award. This delivery order is a child contract executed under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated...
- The Defense Logistics Agency awarded a delivery order valued at $91,225.90 to AmerisourceBergen Drug Corp for the supply of Repatha 140 mg/ml SureClick auto-injector pens. This firm fixed-price delivery order, issued on September 18, 2025, with an ultimate completion date of September 19, 2025, represents a non-competitive award under an existing contract vehicle. The work will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility, the company's corporate headquarters and a...
- The Defense Logistics Agency awarded a delivery order valued at $1,041.42 to AmerisourceBergen Drug Corp for the supply of Repatha 140 mg/ml SureClick auto-injector pens, with an ultimate completion date of August 5, 2025. This non-set-aside, competitively awarded contract employs firm fixed price terms and represents a child delivery order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The product will be delivered to the company's facility in...
- The Defense Logistics Agency awarded a delivery order valued at $13,727.57 to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injector pens. This non-competitive, firm fixed-price delivery order was awarded on September 9, 2025, with a completion date of September 10, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Repatha (evolocumab) is a PCSK9 inhibitor used to lower cholesterol and reduce cardiovascular risk in eligible...
- The Defense Logistics Agency awarded a delivery order valued at $2,648.59 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injector pens, with an ultimate completion date of September 12, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The award reflects AmerisourceBergen's role as a critical pharmaceutical distributor supporting federal medical procurement, particularly for military and veteran healthcare systems. The place of...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,594.36 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injector pens on September 22, 2025, with an ultimate completion date of September 23, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's Conshohocken, Pennsylvania facility. Repatha is a prescription medication used to lower cholesterol levels and reduce the...
- The Defense Logistics Agency awarded a $27,608.80 delivery order to AmerisourceBergen Drug Corp on October 24, 2025, for the supply of Repatha 140 mg/ml SureClick auto-injector pens. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The product will be performed at AmerisourceBergen's location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $10,575.52 to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injector pens under a firm fixed price contract. The award was made on August 27, 2025, with an ultimate completion date of August 28, 2025, and represents a non-set-aside competitive procurement. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office...
- SPE2DB25D2203Indefinite Delivery Contract
- SPE2DB25D2203-SPE2DB26FPRASDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Repatha 140 mg/ml SureClick auto-injector pens, valued at $2,003.48. The award was made on October 30, 2025, under a firm fixed-price delivery order contract with an ultimate completion date of October 31, 2025. This non-set-aside delivery order will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania facility, where the company maintains its corporate operations and serves as a primary pharmaceutical distributor for federal medical procurement initiatives. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of medications and medical supplies to support military healthcare programs worldwide. Repatha is a PCSK9 inhibitor used in cardiovascular disease management, and this delivery order fulfills a specific medical supply requirement within the DLA's broader pharmaceutical procurement strategy supporting Defense Health Agency operations and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.0k | 10/30/25 |